All Healthcare articles – Page 7
-
White papersCan coronavirus vaccines be distributed equitably?
As effective Covid-19 vaccines are rolled out, equitable global access is emerging as a concern. In the seventh article in our pandemic series, Sarah Swartz looks at Covid-19 vaccine distribution and how we engage with companies on this issue.
-
White papersUS healthcare in a post-pandemic world
The COVID-19 pandemic has revealed systemic weaknesses and technological strengths and could speed the kind of progress and change needed for better quality, more accessible and more affordable care. Already, in both the healthcare and IT sectors, leaders and first movers have emerged providing solutions for the medical and social issues the crisis has brought to the fore.
-
White papersThe US election and Covid-19 vaccines: implications for the economy and markets
Joe Biden has been elected 46th president of the United States, and it is likely that he will preside over a divided Congress, with the Republicans maintaining their Senate majority. US voters, like the markets, appear to prefer a balance of power. While President Trump has contested the election results in numerous states, President-elect Biden is likely to be confirmed.
-
White papersImpact investing: a key role to play in reshaping the future
Today, the world is confronting the global coronavirus pandemic, which has put a severe strain on health systems and economies worldwide.
-
White papersThe Golden Age of Health Care Innovation Meets Rising Global Need
Innovative new treatments are revolutionizing medical care to meet the growing needs of an aging global population.
-
White papersThe vaccine is a binary event for the markets, not for the economy
Since the announcements of the discovery of a very effective vaccine, first by Pfizer-BioNTech and then by Moderna and AstraZeneca, the horizon has opened up. Investors are beginning to dream of a world immune to Covid-19. But one swallow doesn’t make a spring. Many unknowns remain (see p.4) and the Covid-19 crisis will leave lasting traces in the economy going forward.
-
White papersExtreme makeover – Changing the face of REITs
At the height of the first wave of the COVID-19 pandemic, the listed real estate sector looked in need of an extreme makeover. Prices of real estate investment trusts (REITs) tumbled more precipitously than those of other asset classes as markets assumed the most pessimistic outcomes of restrictions on movement and lockdowns.
-
White papersGlobal Investment Views - December 2020
As we approach year-end, markets can count on two pieces of news to propel some optimism. The first comes from the US, where the Biden victory, without a real Blue Wave, is seen by markets as the best possible outcome.
-
White papersLocking Down to Speed Opening Up
November’s U.S. and E.U. flash PMIs may begin to teeter, and initial claims could show initial signs of greater layoffs as more shutdowns are enacted across the Western world. The vaccines present compelling data as Phase 3 trials show strong efficacies for preventing infections.
-
White papersSocial bonds: financing the recovery and long-term inclusive growth
With its triple impact on education, income and health, the Covid-19 crisis has exacerbated existing inequalities, both among and within countries. An additional 71 million people, concentrated in South Asia and Sub-Saharan Africa, could be pushed into extreme poverty in 2020 as a result of the pandemic.
-
White papersThe Election Is Finally Here: But What Does It Mean?
How will the election shift U.S. economic policy? Will Biden reshape American infrastructure, energy production and healthcare? How does a second Trump term differ from his first? The Investment Institute hosted public and private markets investors to examine the November 3 vote.
-
White papersA Vaccine to End All Lockdowns?
Vaccine progress led a rally in stocks, though questions remain. The PBOC is expected to keep policy steady at its November meeting amid a recovering economy, and despite positive data, full recovery in U.S. employment isn’t likely until greater childcare options are available.
-
White papersThe coronavirus and its impact on SDG 8
How can the actions of companies affect Sustainable Development Goal (SDG) 8: economic growth and decent work for all? Has the coronavirus interrupted progress towards this goal? To find out, tune in to Fundamentals.
-
White papersMarkets Unscripted: 2020 U.S. Election Series
Ashok Bhatia, Neuberger Berman Deputy CIO – Fixed Income, shares his perspective on investment implications as a result of the U.S. election and recent COVID-19 vaccine news.
-
White papersHow ocean states can benefit from a ‘blue recovery’ from COVID-19
Investing in ocean health offers coastal countries the means to recover from the pandemic in a sustainable and economically efficient manner.
-
White papersMoving the Needle
The U.S. election will be big news in November, but news on coronavirus vaccines will probably “move the needle” more for markets.
-
White papersSo How About that Vaccine?
How close is a vaccine? Who will make money? What’s the impact to other health care sectors? Alexandra Hillier, Ben Eaton & Akan Oton join the Investment Institute and discuss public and private markets on what keeps us up at night (and home much of the day).
-
White papersTakeda Pharmaceutical - UK Institutional
Takeda Pharmaceutical has significantly improved the transparency and accountability of its executive remuneration, aligning itself more closely to global peers.
-
White papersCorona hasn’t changed the climate crisis
The corona crisis, the US elections, trade wars… the climate problem remains. And also the need for an investment strategy that specifically responds to climate change. If anything, the health crisis has created additional opportunities to outperform the market this year due to stimulus for green sectors, argue Ulrik Fugmann and Edward Lees, who head the Environmental Strategies Group at BNP Paribas Asset Management.
-
White papersThe coronavirus and the race for a vaccine
Across the globe, scientists are hunting for an effective vaccine that will end Covid-19. In the sixth article in our pandemic series, Katie Frame looks at the response from the pharmaceutical sector and how we engage on this issue.
